

Opko Health, Inc.
Form 8-K
April 01, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 1, 2016

OPKO Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33528

75-2402409

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

4400 Biscayne Blvd., Miami, Florida

33137

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(305) 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2016, the Compensation Committee of the Board of Directors (the Committee) of OPKO Health, Inc. (the Company) held a meeting to review certain compensation matters for the Company's executive officers and non-executive employees. At the meeting, the Committee granted stock options to the Company's named executive officers to purchase the number of shares of the Company's common stock set forth opposite their names below. The stock options vest ratably over four years and expire on the tenth anniversary of the grant date.

Name	Title	Stock Options
Phillip Frost	Chairman/Chief Executive Officer	500,000
Jane H. Hsiao	Vice Chairman/Chief Technical Officer	450,000
Steven D. Rubin	Executive Vice President	450,000
Adam Logal	Senior Vice President/Chief Financial Officer	250,000

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

April 1, 2016

By: *Adam Logal*

Name: Adam Logal

Title: Senior Vice President-Chief Financial Officer